Publication:
Areas of uncertainty in the management of human trichinellosis: A clinical perspective

dc.contributor.authorGeorge Watten_US
dc.contributor.authorUdomsak Silachamroonen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-24T03:44:21Z
dc.date.available2018-07-24T03:44:21Z
dc.date.issued2004-01-01en_US
dc.description.abstractThere is disagreement between authorities on most facets of trichinellosis therapy. The most controversial issues are when to use corticosteroids and which antihelminthic drug should be administered, for how long and at what dose. These issues are particularly important in the treatment of severe, potentially fatal infections. A major reason for the lack of consensus regarding trichinellosis management is that there have been very few prospective, controlled clinical trials of this infection. After a brief review of pertinent epidemiological and clinical features of the disease, selected treatment concerns will be discussed and areas where more information is urgently required will be highlighted. © Future Drugs Ltd. All rights reserved.en_US
dc.identifier.citationExpert Review of Anti-Infective Therapy. Vol.2, No.4 (2004), 649-652en_US
dc.identifier.doi10.1586/14787210.2.4.649en_US
dc.identifier.issn14787210en_US
dc.identifier.other2-s2.0-4444295856en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/21410
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=4444295856&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleAreas of uncertainty in the management of human trichinellosis: A clinical perspectiveen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=4444295856&origin=inwarden_US

Files

Collections